#United States #Princeton #CytoSorbents #Blood Purification #EACTS

CytoSorbents Showcases Innovative Data in Global Medical Conferences for Cardiac Surgery and Critical Care

CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in the treatment of severe conditions in intensive care and cardiac surgery, is gearing up for significant presentations at two major international conferences. These events will take place in October 2026 and are focused on groundbreaking advancements in cardiac surgery and critical care medicine.

The first of these conferences is the Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS), scheduled for October 7-10, 2026, in Barcelona, Spain. Recognized as the world's largest cardiothoracic surgery conference, EACTS will spotlight innovations and surgical techniques related to heart and lung conditions. CytoSorbents is set to showcase its flagship product, CytoSorb®, which plays a vital role in blood purification during surgeries.

Key presentations include:

• - Prof. Michael Schmoeckel from Ludwig Maximilian University in Munich will discuss intraoperative hemoadsorption aimed at reducing bleeding during isolated CABG procedures, especially for patients under dual P2Y12 inhibitor and DOAC treatments.
• - Prof. Federico Papallardo from San Raffaele University in Milan will present real-world data from the international COSMOS registry, focusing on hemoadsorption applications to treat postoperative vasoplegia and inflammation during VA-ECMO.
• - On October 9, Prof. Endre Nemeth from the Heart and Vascular Centre in Budapest will highlight improved outcomes for high-risk heart transplant patients receiving adjunctive hemoadsorption.

Following EACTS, CytoSorbents will also participate in the European Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon, Portugal, from October 10-14, 2026. This congress is among the leading international gatherings dedicated to critical care, providing a platform for discussion on the latest research, treatments, and guidelines in intensive care medicine. Presentations from this congress include:

• - Prof. Ricard Ferrer, representing Vall d'Hebron Hospital in Barcelona, will share findings from the COSMOS Registry on liver support using hemoadsorption.
• - Further talks will investigate hemoadsorption's effectiveness in managing hyperinflammation and vasoplegia post-surgery, offering promising insights from both preliminary and comprehensive longitudinal studies.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, expressed excitement regarding the diverse clinical data accepted for presentation at these prestigious conferences. He stated, "We are pleased to see a broad spectrum of clinical data on CytoSorb accepted at two of the world's leading cardiac surgery and critical care conferences. These presentations address crucial unmet medical needs in cardiac surgery, like blood thinner removal, heart transplantation, and shock management, alongside critical care treatments for conditions such as septic shock and acute respiratory distress syndrome."

With these events coinciding with Sepsis Awareness Month, the discussions reaffirm the urgent need for effective treatments to combat life-threatening inflammation and organ dysfunction. CytoSorb, known for its innovative blood purification technology, targets the removal of inflammatory mediators and toxins in various critical illnesses, including sepsis, trauma, and liver failure.

Founded on the principles of blood purification, CytoSorbents utilizes proprietary polymer beads capable of effectively extracting harmful substances from blood, facilitating safer surgical procedures and improved patient outcomes across numerous critical conditions.

As the company continues to push boundaries in ICU and cardiac surgery treatment, its ongoing commitment to clinical research and evidence generation through the COSMOS Registry serves to enhance understanding and efficacy in real-world applications of CytoSorb. This international registry systematically collects data from numerous centers, monitoring outcomes, therapy timing, and patient selection, proving instrumental for clinicians worldwide.

In conclusion, CytoSorbents' engagement in these international dialogues highlights its determination to innovate and improve treatments for critically ill patients. With presentations at both EACTS and ESICM, the company looks to cement its position at the forefront of blood purification technology.

For more information about CytoSorbents and its life-saving technologies, you can visit their official website or follow them on social media channels.